Economy

ADB flags cancer treatment shortcomings as case count rises in Asia

REUTERS

ASIAN GOVERNMENTS must innovate in how they support cancer care, which is underfunded even while the incidence of cancer rises, the Asian Development Bank (ADB) said.

“Compared to COVID-19, cancer is a long-term challenge for healthcare systems. No lockdowns can stop or slow the emergence of cancer incidences,” the ADB said in a blog.

“There is a massive gap in annual investment in public healthcare, with investment of less than $100 per capita in countries such as India, Indonesia, the Philippines, and Vietnam compared to more than $3,500 per capita in Japan,” it added.

The ADB said that half of all cancer patients and their households in Southeast Asia face “financial catastrophe” from high medical expenditures.

In Asia, the annual number of new cancer cases increased from 4.9 million in 2002 to 9.5 million in 2020. 

“The pandemic has put a spotlight on health system resilience around the world. Demands on healthcare provision have skyrocketed in record time and brought some healthcare systems to the brink of collapse. Public funds to purchase testing equipment, protective equipment, and later on also vaccines were cleared quickly,” the bank said.

“The COVID-19 pandemic has created tremendous momentum in the field of healthcare. However, the long-term challenge for health systems in Asia lies with non-communicable diseases, in particular cancer, spurred by shifting demographics. There is an urgent need to address the growing demands in cancer care,” it added. 

The ADB recommended that governments include new value- and evidence-based medicines in national formularies in order to maximize positive patient outcomes with limited resources.

“Health technology assessment is a tool to support evidence-based reimbursement decision-making for inclusion in national formularies, but its use is still in its infancy in many Asian countries,” it said.

Governments must also stimulate competition among pharmaceutical producers to raise capital.

“With the first wave of modern cancer medicines launched at the turn of the millennium going off- patent now, the use of biosimilars and generics instead of the originator medicines deserves greater attention,” it said.

“Generic brand competition and stricter price control of originator medicines after patent expiry could create considerable budget headroom for governments. A published estimate of a basket of cancer medicines with generic brands points to savings opportunities of around 3%-20% of total cancer medicine expenditure in Asia and the Pacific region,” it added.

These funds can be channeled into innovative medicines to offer a more sustainable financing model while improving patient outcomes. — Luisa Maria Jacinta C. Jocson

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top